IO Biotech (NASDAQ:IOBT) has filed for the sale of up to 5.6M shares of common stock for holders. Filing IO Biotech GAAP EPS of -$0.34 beats by $0.11 Seeking Alpha’s Quant Rating on IO Biotech ...

NEW YORK - IO Biotech (IOBT), a clinical-stage biopharmaceutical firm with a market capitalization of approximately $61 million, has presented new preclinical data on two therapeutic cancer ...

IO Biotech (NASDAQ:IOBT – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $12.00 ...

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

IO Biotech, Inc., a pharmaceutical company with a market capitalization of $62 million, has been notified by The Nasdaq Stock Market LLC of non-compliance with its minimum bid price requirement.

Despite this notice, there is no immediate impact on the listing of IO Biotech’s common stock on the Nasdaq Global Select Market. The company will continue to trade on this platform. As per ...

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ...

NEW YORK, November 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology ...

A webcast replay of the presentations will be available on IO Biotech’s website at www.iobiotech.com for 90 days following the presentation. IO Biotech is a clinical-stage ...

Fintel reports that on August 11, 2023, HC Wainwright & Co. reiterated coverage of IO Biotech (NASDAQ:IOBT) with a Buy recommendation. As of August 2, 2023, the average one-year price target for ...